GRONINGEN, The Netherlands - October 26, 2004 - IQ Corporation (IQC), a Dutch biopharmaceutical company specializing in the development of fully human antibody therapy products, announced the addition of Willem Hazenberg, PhD. who will be responsible for leading the global business development efforts for the company.
Dr. Hazenberg will focus in particular on the commercialization and partnering of a number of fully human monoclonal antibody products IQC is developing for infectious disease and biodefense indications. IQC's two lead human antibody products are directed against two different components of the lethal toxin of anthrax.
Prior to joining IQ Corporation, Dr. Hazenberg worked as Business Development and Investments Director for Medabiotech SA in Geneva, where he served as investment manager for the company's venture fund. His eight years of industry experience also includes previous positions with Cytos Biotechnology AG in Zurich and involvement in the creation and financing of a number of start-up biotech companies as entrepreneur, venture consultant and investor.
"Dr. Hazenberg will be a great addition to IQ Corporation," said Dr. Roland Lageveen, Ph.D., CEO of IQ Corporation. "The combination of his expertise in the biotechnology industry and his business development background will be crucial in helping IQ Corporation meet its growth and funding projections in the coming year."
About IQ Corporation
IQ Corporation (IQ) is a life sciences company based in The Netherlands. Its mission is to profitably contribute to human healthcare through the development and worldwide commercialization of antibodies for diagnostic and therapeutic applications. The company's therapeutics division (IQ Therapeutics) has developed a method for the generation of fully human antibodies from immunized donors. This Cloning the Human Response™ technology enables IQ to obtain fully human antibodies for therapeutic and prophylactic applications, thus delivering Immunity from a Vial™. The company's diagnostic products division (IQ Products) has developed a range of products for flow-cytometry and viral diagnostics, which are sold in more than 60 countries.
Noot voor de pers: meer informatie over IQ Corporation vindt u op www.iqcorporation.nl. U kunt ook contact opnemen met Herman Groen, Chief Scientific Officer (h.groen@iqtherapeutics.nl) of met Roland Lageveen (r.lageveen@iqcorporation.nl), Chief Executive Officer van IQ Corporation, telefoon: 050.5757010.
Nederlands perscontact: Wisse Kommunikatie, Hubert Wisse, telefoon: 026.4431523 of per e-mail: hubert-wisse@wisse-worldcom.nl.